Literature DB >> 12370165

Empirically calibrated model of hepatitis C virus infection in the United States.

Joshua A Salomon1, Milton C Weinstein, James K Hammitt, Sue J Goldie.   

Abstract

This study presents a comprehensive epidemiologic model of hepatitis C in the United States. Through empirical calibration of model parameter values, the objectives were to gain insights into uncertain aspects of the natural history of hepatitis C and to improve the basis for projecting the future course of the epidemic. A systematic review of the published literature was conducted to define plausible ranges around model parameters, and multiple simulations of the model were undertaken using sampled values from these ranges. Model predictions produced by each set of sampled values were compared with available epidemiologic data on infection prevalence and mortality from liver cancer, and various goodness-of-fit criteria were used to identify the range of parameter values that were consistent with these data. The results of the study indicate that rates of progression to advanced liver disease may be lower than previously assumed. The authors also found that a wide range of plausible assumptions about heterogeneity in these rates, beyond that explained by age and sex, is consistent with observed epidemiologic trends. These findings have important implications both for individual clinical decisions and for broader public health policy.

Entities:  

Mesh:

Year:  2002        PMID: 12370165     DOI: 10.1093/aje/kwf100

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  39 in total

1.  Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial.

Authors:  Christopher H Jackson; Mark Jit; Linda D Sharples; Daniela De Angelis
Journal:  Med Decis Making       Date:  2013-07-25       Impact factor: 2.583

Review 2.  Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.

Authors:  Sun-Young Kim; Sue J Goldie
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 3.  Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma.

Authors:  Amir Shlomai; Ype P de Jong; Charles M Rice
Journal:  Semin Cancer Biol       Date:  2014-01-20       Impact factor: 15.707

Review 4.  Estimating the true prevalence of hepatitis C in rhode island.

Authors:  Elizabeth N Kinnard; Lynn E Taylor; Omar Galárraga; Brandon D L Marshall
Journal:  R I Med J (2013)       Date:  2014-07-01

5.  Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settings.

Authors:  April D Kimmel; Daniel W Fitzgerald; Jean W Pape; Bruce R Schackman
Journal:  Med Decis Making       Date:  2014-10-20       Impact factor: 2.583

6.  Postharvest Supply Chain with Microbial Travelers: a Farm-to-Retail Microbial Simulation and Visualization Framework.

Authors:  Claire Zoellner; Mohammad Abdullah Al-Mamun; Yrjo Grohn; Peter Jackson; Randy Worobo
Journal:  Appl Environ Microbiol       Date:  2018-08-17       Impact factor: 4.792

Review 7.  Dynamic microsimulation models for health outcomes: a review.

Authors:  Carolyn M Rutter; Alan M Zaslavsky; Eric J Feuer
Journal:  Med Decis Making       Date:  2010-05-18       Impact factor: 2.583

8.  The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States.

Authors:  Vikrant V Sahasrabuddhe; Meredith S Shiels; Katherine A McGlynn; Eric A Engels
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

9.  Using Observational Data to Calibrate Simulation Models.

Authors:  Eleanor J Murray; James M Robins; George R Seage; Sara Lodi; Emily P Hyle; Krishna P Reddy; Kenneth A Freedberg; Miguel A Hernán
Journal:  Med Decis Making       Date:  2017-11-15       Impact factor: 2.583

Review 10.  Recent developments in decision-analytic modelling for economic evaluation.

Authors:  Milton C Weinstein
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.